Заснована на

References

1. Robinson KA, Saldanha I, McKoy N. Management of infants with cystic

fibrosis: A summary of the evidence for the Cystic Fibrosis Foundation

Working Group on Care of Infants with Cystic Fibrosis. J Pediatr

(Insert proper citation for the submitted methodology paper in this

supplement).

2. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update

on the methods of the US Preventive Services Task Force: estimating

certainty and magnitude of net benefit. Ann Intern Med 2007;147:

871-5.

3. Giglio L, Candusso M, D’Orazio C, Mastella G, Faraguna D. Failure to

screening. Acta Paediatr 1997;86:1162-5.

4. Accurso FJ, Sontag MK, Wagener JS. Complications associated with

symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005;

147(suppl):S37-41.

5. Jedlicka-Kohler I, Gotz M, Eichler I. Parents’ recollection of the initial

communication of the diagnosis of cystic fibrosis. Pediatrics 1996;97:

204-9.

7. Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, et al.

Economic implications of newborn screening for cystic fibrosis: a cost

of illness retrospective cohort study. Lancet 2007;369:1187-95.

8. 9Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-

based practice recommendations for nutrition-relatedmanagement

of children and adults with cystic fibrosis and pancreatic insufficiency: results

of a systematic review. J Am Diet Assoc 2008;108:832-9.

9. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R,

Wagener JS, et al. Growth and nutritional indexes in early life predict

pulmonary function in cystic fibrosis. J Pediatr 2003;142:624-30.

10. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ,

Sokol RJ. Prospective, long-term study of fat-soluble vitamin status

in children with cystic fibrosis identified by newborn screen. J Pediatr

1999;135:601-10.

11. Shepherd RW, Holt TL, Greer R, Cleghorn GJ, Thomas BJ. Total body

potassium in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:200-5.

12. Borowitz D. Update on the evaluation of pancreatic exocrine status in

cystic fibrosis. Curr Opin Pulm Med 2005;11:524-7.

13. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB,

Hambridge KM, et al. Pancreatic insufficiency, growth, and nutrition

in infants identified by newborn screening as having cystic fibrosis.

J Pediatr 1992;120:533-40.

14. Walkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert K,

Herzig KH, et al. Early decline of pancreatic function in cystic fibrosis

patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr

2005;40:199-201.

15. Gaskin K, Waters D, Dorney S, Gruca M, O’Halloran M, Wilcken B. Assessment

of pancreatic function in screened infants with cystic fibrosis.

Pediatr Pulmonol Suppl 1991;7:69-71.

16. Bellentani S, Grisendi A, Rinaldi M, Bertolani P, Costa G, Agostini M,

et al. BT-Paba test in the diagnosis of pancreatic exocrine insufficiency

in cystic fibrosis: urinary and serum determinations compared. Eur J

Pediatr 1984;143:145-8.

17. Greer R, Shepherd R, Cleghorn G, Bowling FG, Holt T. Evaluation of

growth and changes in body composition following neonatal diagnosis

of cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;13:52-8.

18. Durie PR, Largman C, Brodrick JW, Johnson JH, Gaskin KJ,

Forstner GG, et al. Plasma immunoreactive pancreatic cationic trypsinogen

in cystic fibrosis: a sensitive indicator of exocrine pancreatic dysfunction.

Pediatr Res 1981;15:1351-5.

19. Gillard BK, Cox KL, Pollack PA, Geffner ME. Cystic fibrosis serum pancreatic

amylase: useful discriminator of exocrine function. Am J Dis

Child 1984;138:577-80.

20. Watkins JB, Schoeller DA, Klein PD, Ott DG, Newcomer AD,

Hofmann AF. 13C-trioctanoin: a nonradioactive breath test to detect

fat malabsorption. J Lab Clin Med 1977;90:422-30.

21. Colombo C, Maiavacca R, Ronchi M, Consalvo E, Amoretti M,

Giunta A. The steatocrit: a simple method for monitoring fat malabsorption

in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr

1987;6:926-30.

22. Remtulla MA, Durie PR, Goldberg DM. Stool chymotrypsin activity

measured by a spectrophotometric procedure to identify pancreatic

disease in infants. Clin Biochem 1986;19:341-7.

23. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal

pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr

2002;141:84-90.
Джерело: Peter J. Mogayzel et al. Cystic Fibrosis Pulmonary Guidelines Chronic Medications for Maintenance of Lung Health Am J Respir Crit Care Med Vol 187, Iss. 7, pp 680–689, Apr 1, 2013

1. Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr,

Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al.

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance

of lung health. Am J Respir Crit Care Med 2007;176:957–969.

2. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on

the methods of the US Preventive Services Task Force: estimating certainty

and magnitude of net benefit. Ann Intern Med 2007;147:871–875.

3. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis.

Cochrane Database Syst Rev 2005;CD003428.

4. König P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial

of the long-term effects of albuterol administration in patients with

cystic fibrosis. Pediatr Pulmonol 1998;25:32–36.

5. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner

RA. A controlled trial of long-term bronchodilator therapy in cystic

fibrosis. Chest 1991;99:1088–1092.

6. Holzer FJ, Olinsky A, Phelan PD. Variability of airways hyper-reactivity

and allergy in cystic fibrosis. Arch Dis Child 1981;56:455–459.

7. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose

ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:

848–854.

8. Konstan MW, Hoppel CL, Chai BL, Davis PB. Ibuprofen in children

with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr

1991;118:956–964.

9. Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC. A preliminary study

on the effect of anti-inflammatory treatment in cystic fibrosis patients

with Pseudomonas aeruginosa lung infection. Int J Immunopathol

Pharmacol 1994;7:109–117.

10. Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose

ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial.

J Pediatr 2007;151:249–254.

686 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 187 2013

11. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy

for cystic fibrosis. Cochrane Database Syst Rev 2007;CD001505.

12. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA,

Hilliard JB, Davis PB, Hoppel CL. Effect of ibuprofen on neutrophil

migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol

Exp Ther 2003;306:1086–1091.

13. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long

term effects of azithromycin in patients with cystic fibrosis: a double

blind, placebo controlled trial. Thorax 2006;61:895–902.

14. Rotschild M, Elias N, Berkowitz D, Pollak S, ShinawiM, Beck R, Bentur

L. Autoantibodies against bactericidal/permeability–increasing protein

(BPI-ANCA) in cystic fibrosis patients treated with azithromycin.

Clin Exp Med 2005;5:80–85.

15. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL,

Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW

III. Azithromycin in patients with cystic fibrosis chronically infected

with Pseudomonas aeruginosa: a randomized controlled trial. JAMA

2003;290:1749–1756.

16. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of

long term treatment with azithromycin on disease parameters in cystic

fibrosis: a randomised trial. Thorax 2002;57:212–216.

17. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M,

Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al.

Effect of azithromycin on pulmonary function in patients with cystic

fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled

trial. JAMA 2010;303:1707–1715.

18. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin

in children with cystic fibrosis: A randomised, placebocontrolled

crossover trial. Lancet 2002;360:978–984.

19. Southern K, Barker P, Solis-Moya A, Patel L. Macrolide antibiotics for

cystic fibrosis. Cochrane Database Syst Rev 2004;CD002203.

20. Loening-Baucke VA, Mischler E, Myers MG. A placebo-controlled trial

of cephalexin therapy in the ambulatory management of patients with

cystic fibrosis. J Pediatr 1979;95:630–637.

21. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis

in infants and young children with cystic fibrosis: a randomized

controlled trial. J Pediatr 2002;140:299–305.

22. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane

Database Syst Rev 2003;CD001912.

23. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A,

Joubran J, Seepersaud S, Sussky K, et al. Ivacaftor potentiation of

multiple CFTR channels with gating mutations. J Cyst Fibros 2012;11:

237–245.

24. Yang Y, Devor DC, Engelhardt JF, Ernst SA, Strong TV, Collins FS,

Cohn JA, Frizzell RA, Wilson JM. Molecular basis of defective anion

transport in L cells expressing recombinant forms of CFTR. Hum Mol

Genet 1993;2:1253–1261.

25. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel

SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect ofVX-770

in persons with cystic fibrosis and the G551D-CFTR mutation.NEngl J

Med 2010;363:1991–2003.

26. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P,

Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR

potentiator in patients with cystic fibrosis and the G551D mutation.

N Engl J Med 2011;365:1663–1672.

27. Aherns RS, Yen K, Davies JC. VX-770 in subjects 6 to 11 years with

cystic fibrosis and the G551D-CFTR mutation [abstract]. Pediatr

Pulmonol 2011;46 (S34):283.

28. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller

DE. Ivacaftor in subjects with cystic fibrosis who are homozygous for

the F508del-CFTR mutation. Chest 2012;142:718–724.

29. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas

aeruginosa and other predictors of mortality and morbidity in

young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91–100.

30. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ,

Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas

aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;

178:921–928.

[1] DiSant'Agnese PA. Cystic fibrosis of the pancreas. Am J Med

1956;21:406–22.

[2] Shwachman H, Kulczycki LL. Long-term study of one hundred five

patients with cystic fibrosis; studies made over a five- to fourteen-year

period. AMA J Dis Child 1958;96:6–15.

[3] Doershuk CF, Matthews LW, Tucker AS, Nudleman H, Eddy G, Wise

M, et al. A 5 year clinical evaluation of a therapeutic program for

patients with cystic fibrosis. J Pediatr 1964;65:677–93.

[4] Warwick WJ, Pogue RE. The prognosis for children with cystic

fibrosis based on reasoned approaches to therapy: past, present, and

future. J Asthma Res 1968;5:277–84.

[5] Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: a new

outlook. 70 patients above 25 years of age. Medicine 1977;56:129–49.

[6] Crozier DN. Cystic fibrosis: a not-so-fatal disease. Pediatr Clin North

Am 1974;21:935–50.

[7] Gurwitz D, Corey M, Francis PW, Crozier D, Levison H. Perspectives

in cystic fibrosis. Pediatr Clin North Am 1979;26:603–15.

[8] Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of

survival, growth, and pulmonary function in patients with cystic

fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583–91.

[9] Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient

Registry 2011 annual data report; 2012 [Bethesda, Maryland].

[10] Cystic Fibrosis Canada. Canadian Cystic Fibrosis Patient Data

Registry report. 2010; 2011 [Toronto].

[11] Cystic Fibrosis Foundation. http://www.cff.org/LivingWithCF/Care

CenterNetwork/QualityImprovement/; 2013.

[12] Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D,

et al. An overview of international literature from cystic fibrosis

registries. Part 4: update 2011. J Cyst Fibros 2012;11:480–93.

[13] European cystic fibrosis society patient registry newsletter.

http://www.ecfs.eu/projects/ecfspr/newsletters; January 2013 . [Issue

3].

[14] The ECFS Patient Registry annual data report. 2008–2009 data.

https://www.ecfs.eu/files/webfm/webfiles/File/ecfs_

registry/ECFSPR_Report0809_v32012.pdf; 2012.

[15] Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter

H, et al. Factors associated with FEV1 decline in cystic fibrosis:

analysis of the data of the ECFS Patient Registry. Eur Respir J 2013.

http:// dx.doi.org/10.1183/09031936.00166412 [Epub ahead of print].

[16] Wiedemann B, Steinkamp G, Sens B, Stern M. The German Cystic

Fibrosis Quality Assurance Project: clinical features in children and

adults. Eur Respir J Eur Respir J 2001;17:1187–94.

[17] Gutierrez HH, Sanchez I, Schidlow DV. Cystic fibrosis care in Chile.

Curr Opin Pulm Med 2009;15:632–7.

[18] Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC,

Geller DE, et al. Epidemiologic study of cystic fibrosis: design and

implemen- tation of a prospective, multicentre, observational study of

patients with cystic fibrosis in the U.S. and Canada. Pediatr Pumonol

1999;28:231–41.

[19] Schechter MS. Benchmarking to improve the quality of cystic fibrosis

care. Curr Opin Pulm Med 2012;18:596–601.

[20] Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G,

Graff GR, et al. Baseline characteristics and factors associated with

nutritional and pulmonary status at enrollment in the cystic fibrosis

EPIC observational cohort. Pediatr Pulmonol 2010;45:934–44.

[21] Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper

PJ, et al. Prospective evaluation of respiratory exacerbations in

children with cystic fibrosis from newborn screening to 5 years of age.

Thorax 2013;68:643–51.

[22] Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S.

Comparison of the US and Australian cystic fibrosis registries: the

impact of newborn screening. Pediatrics 2012;129:48–55.

[23] Closing the quality gap: revisiting the state of the science series:

quality improvement interventions to address health disparities.

Review protocol. Rockville, MD: Agency for Healthcare Research

and Quality; 2011 [http://www.ahrq.gov/clinic/tp/gapdisptp.htm].

[24] Berwick DM. The science of improvement. JAMA 2008;299:1182–4.

[25] Shojania KG, Grimshaw JM. Evidence-based quality improvement:

the state of the science. Health Aff (Millwood) 2005;24:138–50.

[26] Berwick DM. Continuous improvement as an ideal in health care. N

Engl J Med 1989;320:53–6.

[27] Nelson EC, Godfrey MM, Batalden PB, Berry SA, Bothe AE,

McKinley KE, et al. Clinical microsystems, Part1: The building

blocks of health systems. Jt Comm J Qual Patient Saf 2008;34:367–

78.

from cystic fibrosis. J Pediatr 2005;147:295–301.

[29] Quinton HB, O'Connor GT, for the Northern New England CV Cystic

Fibrosis Consortium. Current issues in quality improvement in cystic

fibrosis. Clin Chest Med 2007;28:459–72.

[30] Stern M, Wiedemann B, Wenzlaff P, on behalf of the German Cystic

Fibrosis Quality Assessment group. From registry to quality management:

the German Cystic Fibrosis Quality Assessment project 1995–

2006. Eur Respir J 2008;31:29–35.

[31] Stern M. The use of a cystic fibrosis patient registry to assess

outcomes and improve cystic fibrosis care in Germany. Curr Opin

Pulm Med 2011;17:477–573.

[32] Ellemunter H, Eder J, Steinkamp G. Structured care in an ISO

certified Centre for patients with cystic fibrosis and their families.

Pneumologie 2011;65:615–23.

[33] Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ,

et al. Year-to-year changes in lung function in individuals with cystic

fibrosis. J Cyst Fibros 2010;9:250–6.

[34] Taylor-Robinson D, Whitehead M, Diderichsen F, Vebert Olesen H,

Pressler T, Smyth RL, et al. Understanding the natural progression in

%FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Thorax 2012;67:860–6.

[35] Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF,

Robinson P, et al. Infection, inflammation and lung function decline in

infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75–

81.

through quality improvement. Semin Respir Crit Care Med

2009;30:547–58.

[37] Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B,

Quittner AL, et al. Measuring and improving respiratory outcomes in

cystic fibrosis lung disease: opportunities and challenges to therapy. J

Cyst Fibros 2010;9:1–16.

[38] Glauser TA, Nevins PH, Williamson JC, Abdolrasulnia M, Salinas

GD, Zhang J, et al. Adherence to the 2007 cystic fibrosis pulmonary

guidelines: a national survey of CF care centers. Pediatr Pulmonol

2012;47:434–40.

[39] McPhail GL, Weiland J, Acton JD, Ednick M, Chima A, VanDyke R,

et al. Improving evidence-based care in cystic fibrosis through quality

improvement. Arch Pediatr Adolesc Med 2010;164:957–60.

[40] Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H.

Evidence-based practice recommendations for nutrition-related

manage- ment of children and adults with cystic fibrosis and

pancreatic insufficiency: results of a systematic review. J Am Diet

Assoc 2008;108:832–9.

[41] Moen IE, Nilsson K, Andersson A, Fagerland MW, Fluge G, Hollsing

A, et al. Dietary intake and nutritional status in a Scandinavian adult

cystic fibrosis population compared with recommendations. Food Nutr

Res 2011;55:7561.

[42] Leonard A, Davis E, Rosenstein BJ, Zeitlin PL, Paranjape SM, Peeler

D, et al. Description of a standardized nutrition classification plan and

its relation to nutritional outcomes in children with cystic fibrosis. J

Pediatr Psychol 2010;35:6–13.

[43] Stark LJ, Opipari-Arrigan L, Quittner AL, Bean J, Powers SW. The

effects of an intensive behavior and nutrition intervention compared to

standard of care on weight outcomes in CF. Pediatr Pulmonol

2011;46:31–5.

[44] Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med

2006;173:475–82.

[45] CF Europe. http://www.cf-europe.eu/.

[46] Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data

Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2011

[http://www.cff.

org/research/ClinicalResearch/PatientRegistryReport].

[47] Goss HG, Quittner AL. Patient-reported outcomes in cystic fibrosis.

Proc Am Thorac Soc 2007;4:378–86.

[48] Mayer-Hamblett N, Ramsey BW, Kronmal AK. Advancing outcome

measures for the new era of drug development in cystic fibrosis. Proc

Am Thorac Soc 2007;4:370–7.

[49] European Medicines Agency. Committee for medicinal products for

Human Use (CHMP). Guidelines on the Clinical Development of

Medicinal Products for the Treatment of Cystic Fibrosis; Oct. 22 2009

[London, http://www.ema.europa.eu/docs/en_GB/document_library/

Scientific_guideline/2009/12/WC500017055.pdf].

[50] Kerem E, Conway S, Elborn S, Heijerman H, for the Consensus

Committee. Standards of care for patients with cystic fibrosis: a

European consensus. J Cyst Fibros 2005;4(7–26):20.

[51] Steinkamp G, Schwarz C, Stahl K, Busche MCF. Care through the

patient's eyes — a nationwide survey on patients' experience and

satisfaction with services using a CF-specific questionnaire. Pediatr

Pulmonol 2012;47(S35):404 (abstract 492).

[52] Quon BS, Goss CH. A story of success: continuous quality

improvement in cystic fibrosis care in the USA. Thorax

2011;66:1106–8.

[53] http://www.cftrust.org.uk/aboutus/annualreview/CF_Trust_Annual_Review_

2011_%28web%29.pdf.

[54] https://www.cysticfibrosis.org.uk/media/82070/CD_Standards_of_Care_

Dec_11.pdf.

[55] http://www.cff.org/treatments/CFCareGuidelines/AgeSpecificCare/.

[56] Batalden PB, Davidoff F. What is “quality improvement” and how can

it transform healthcare? Qual Saf Health Care 2007;16:2–3.

[57] Sermet-Gaudelus I, Mayell SJ, Southern KW. Guidelines on the early

management of infants diagnosed with cystic fibrosis following

newborn screening. J Cyst Fibros 2010;9:323–9.

[58] Mehta G, Macek Jr M, Mehta A, European RegistryWorking Group.

Cystic fibrosis across Europe: EuroCareCF analysis of demographic

data from 35 countries. J Cyst Fibros 2010;9(Suppl. 2):5–21.

[59] World Health Organization. Guidance on developing quality and

safety strategies with a health system approach. Copenhagen: World

Health Organization Regional Office for Europe; 2008.

[60] Stern M, Niemann N, Wiedemann B, Wenzlaff P, German CFQA

Group. Benchmarking improves quality in cystic fibrosis care: a pilot

project involving 12 Centres. Int J Qual Health Care 2011;23:349–56.

[61] Ayers LR, Beyea SC, Godfrey MM, Harper DC, Nelson EC, Batalden

PB. Quality improvement learning collaboratives. Qual Manag Health

Care 2005;14:234–47.

[62] Rault G, Pougheon-Bertrand D, Gueganton L, Minguet G, Lombrail P.

CF quality improvement program: a pilot phase to experiment the US

QIP approach in France. Poster; ECFS Conference, Dublin, Ireland;

June 6–9 2012.

S60 M. Stern et al. / Journal of Cystic Fibrosis 13 (2014) S43–S59

[63] Schechter MS, Leonard A, Nash J, Quinton H, Richards K, Sabadosa

K, et al. Benchmarking: signature themes. Pediatr Pulmonol

2006(Suppl. 29):122–3.

[64] Homchick RG, Hayward LR. Chapter 16. Peer review and quality

assurance requirements. In: Tremaine DW, JD Organization, editors.

3rd ed. Washington Health Law Manual; 2009.

[65] World Health Organization. Quality of care: a process for making

strategic choices in health systems. Geneva: World Health

Organization; 2006.

[66] Nelson EC, Batalden PB, Godfrey M. Measurement and monitoring.

Quality by design: a clinical microsystems approach. Hoboken, NJ:

John Wiley & Sons; 2007.

[67] McIntyre K, Shojania KG. The challenges of quality improvements

reports and the urgent need for more of them. Thorax 2011;66:1020-2.

[68] Shaw CD, Kalo I. A background for national quality policies in health

systems. Copenhagen: World Health Organization Regional Office for

Europe; 2002.

[69] Kulich M, Rosenfeld M, Goss CH, Wilmott R. Improved survival

among young patients with cystic fibrosis. J Pediatr 2003;142:631–6.

[70] Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML.

Developing cystic fibrosis lung transplant referral criteria using

predictors of two year mortality. Am J Respir Crit Care Med

2002;166:1550–5.

[71] Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N,

Boyle MP. Association between respiratory tract methicillin-resistant

Staphylococcus aureus and survival in cystic fibrosis. JAMA

2010;303:2386–92.

[72] Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH. Risk

factors for chronic kidney disease in adults with cystic fibrosis. Am J

Respir Crit Care Med 2011;184:1147–52.

[73] Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A.

Case–control study of acute renal failure in patients with cystic

fibrosis in the UK. Thorax 2008;63:532–5.

[74] Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a

determinant of mortality in cystic fibrosis. Diabetes Care

2010;33:311–6.

[75] Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors

influencing outcomes in cystic fibrosis: a center-based analysis. Chest

2003;123:20–7.

[76] Döring G, Flume P, Heijerman H, Elborn JS. Treatment of lung

infection in patients with cystic fibrosis: current and future strategies.

J Cyst Fibros 2012;11:461–79.

[77] Schechter MS, Gutierrez HH. Improving the quality of care for

patients with cystic fibrosis. Curr Opin Pediatr 2010;22:296–301.

[78] Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to

treating cystic fibrosis pulmonary exacerbations varies widely across

US CF care centers. Pediatr Pulmonol 2011;46:870–81.

[79] Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ,

et al. Progression of early structural lung disease in young children

with cystic fibrosis assessed using CT. Thorax 2012;67:509–16.

[80] Sanders DB, Lai HJ, Rock MJ, Farrell PM. Comparing age of cystic

fibrosis diagnosis and treatment initiation after newborn screening

with two common strategies. J Cyst Fibros 2012;11:150–3.

[81] Calvin J, Hogg SL, McShane D, McAuley SA, Iles R, Ross-Russell R,

et al. Thirty-years of screening for cystic fibrosis in East Anglia. Arch

Dis Child 2012;97:1043–7.

[82] Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ,

Van der Ploeg CP, et al. Novel strategies in newborn screening for

cystic fibrosis: a prospective controlled study. Thorax 2012;67:289–

95.

[83] Walshe K. International comparisons of the quality of health care:

[84] Dreachslin JL, Zernott M, Mendenhall S, Nieuwenjuijsen ER. Data

comparability issues in international research and quality assurance.

Qual Assur Health Care 1993;5:143–56.

[85] Kerr EA, Asch SM, Hamilton EG, McGlynn EA, editors. Quality of

care for general medical conditions: a review of the literature and

quality indicators. Santa Monica, CA: RAND Corporation; 2000.

[86] Marshall MN, Shekelle PG, McGlynn EA, Campbell S, Brook RH,

Roland MO. Can health care quality indicators be transferred between

countries? Qual Saf Health Care 2003;12:8–12.

[87] Ellis J. Sharing the evidence: clinical practice benchmarking to

improve continuously the quality of care. J Adv Nurs 2000;32:215-25.

[88] Goddard M, Mannion R, Smith P. Enhancing performance in health

care: a theoretical perspective on agency and the role of information.

Health Econ 2000;9:95–107.

[89] Sims G. International benchmarking from Centre level cystic fibrosis

data. Pediatr Pulmonol 2010;45(S33):527.

[90] Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J,

Havermans T, et al. European Cystic Fibrosis Society Standards of

Care: framework for the cystic fibrosis centre. J Cyst Fibros

2014;13:3–22.

[91] Gawande A. The bell curve. N Y Ann Med 2004 The New Yorker.

[92] Delaisi B, Grosskopf C, Reignault E, Goehrs JM, Navarro J.

International registry on mucoviscidosis: comparison of the French

data with the European data for 1995. Arch Pediatr 1998;5:384–8.

[93] Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM.

Comparison of growth status of patients with cystic fibrosis between

the United States and Canada. Am J Clin Nutr 1999;69:531–8.

[94] Fogarty A, Hubbard R, Britton J. International comparison of median

age at death from cystic fibrosis. Chest 2000;117:1656–60.

[95] Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M,

et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF):

comparison of major disease manifestations between patients with

different classes of mutations. Pediatr Pulmonol 2001;31:1–12.

[96] McCormick J, Mehta G, Olesen HV, Viviani L, Macek Jr M, Mehta

A, et al.

Comparative demographics of the European cystic fibrosis population:

a cross-sectional database analysis. Lancet 2010;375:1007–13.

[97] Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F,

Laerum BN, et al. Differences in prevalence and treatment of

Pseudomonas aeruginosa in cystic fibrosis Centres in Denmark,

Norway and Sweden. J Cyst Fibros 2009;8:135–42.

[98] Jackson AD, Daly L, Kelleher C, Marshall BC, Quinton HB, Foley L,

et al.

fibrosis median survival internationally is limited. J Cyst Fibros

2011;10:62–5.

[99] Boelle PY, Viviani L, Busson PF, Olesen H, Ravilly S, Stern M, et al.

Reference percentiles for FEV1 and BMI in European children and

adults with cystic fibrosis. Orphanet J Rare Dis 2012;7:64.

[100] Viviani L, Zolin A, Olesen HV. ECFSPR Annual Report 2008–2009.

European Cystic Fibrosis Society Patient Registry; 2012.

[101] McCormick J, Sims EJ, Green MW, Mehta G, Culross F, Mehta A.

Comparative analysis of Cystic Fibrosis Registry data from the UK

with USA, France and Australasia. J Cyst Fibros 2005;4:115–22.

[102] Sims G. International benchmarking for cystic fibrosis patient

outcomes using registry data. J Cyst Fibros 2009;8(S2):S103.

[103] Cystic fibrosis data network.

http://www.cysticfibrosisdata.org/metadata- and-methodology.htm.

[104] Sims G. Outline and proposal for an international Cystic Fibrosis Data

Network. http://www.cfww.org/programs/article/1319/Outline_and_

proposal_for_an_international_Cystic_Fibrosis_Data_Network_April

_ 2010; April 2010